MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

Home・Список акций・Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Закрыт

СекторЗдравоохранение

339.06 1.82

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

329.96

Макс.

343.01

Ключевые показатели
By Trading Economics
Доход	-65M 186M
Продажи	-152M 1.1B
P/E Средняя по отрасли	141.777 66.418
Прибыль на акцию	1.25
Рентабельность продаж	16.993
Сотрудники	2,500
EBITDA	-152M 145M

Рекомендации
By TipRanks
Рекомендации	Активная покупка
Прогноз на 12 месяцев	+35.88% upside

Дивиденды
By Dow Jones
Следующий отчет о доходах	30 апр. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	1.5B 44B
Предыдущая цена открытия	337.24
Предыдущая цена закрытия	339.06

Новостные настроения

By Acuity

50%

154 / 348 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Bullish Evidence

256.565 / 269.81 Поддержка и Сопротивление

Alnylam Pharmaceuticals Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

13 апр. 2026 г., 23:25 UTC

Главные новостные события

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

13 апр. 2026 г., 22:45 UTC

Главные новостные события

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

13 апр. 2026 г., 18:03 UTC

Отчет

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

13 апр. 2026 г., 23:58 UTC

Отчет

Review & Preview: Earnings Time -- Barrons.com

13 апр. 2026 г., 23:49 UTC

Обсуждения рынка

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

13 апр. 2026 г., 23:33 UTC

Обсуждения рынка

Главные новостные события

Gold Edges Higher Amid Dollar Weakness -- Market Talk

13 апр. 2026 г., 23:20 UTC

Обсуждения рынка

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

13 апр. 2026 г., 23:01 UTC

Отчет

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

13 апр. 2026 г., 23:01 UTC

Отчет

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

13 апр. 2026 г., 23:01 UTC

Отчет

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

13 апр. 2026 г., 22:21 UTC

Приобретения, слияния, поглощения

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

13 апр. 2026 г., 21:53 UTC

Отчет

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

13 апр. 2026 г., 21:53 UTC

Отчет

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

13 апр. 2026 г., 21:53 UTC

Отчет

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

13 апр. 2026 г., 21:53 UTC

Отчет

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

13 апр. 2026 г., 21:26 UTC

Главные новостные события

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

13 апр. 2026 г., 21:23 UTC

Отчет

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

13 апр. 2026 г., 21:16 UTC

Отчет

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

13 апр. 2026 г., 20:50 UTC

Обсуждения рынка

Главные новостные события

Basic Materials Roundup: Market Talk

13 апр. 2026 г., 20:50 UTC

Обсуждения рынка

Auto & Transport Roundup: Market Talk

13 апр. 2026 г., 20:34 UTC

Отчет

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

13 апр. 2026 г., 20:34 UTC

Отчет

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

13 апр. 2026 г., 20:34 UTC

Отчет

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

13 апр. 2026 г., 19:59 UTC

Обсуждения рынка

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

13 апр. 2026 г., 19:50 UTC

Обсуждения рынка

Главные новостные события

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

13 апр. 2026 г., 19:27 UTC

Обсуждения рынка

Главные новостные события

Correction to Precious Metals Market Talk on April 9

13 апр. 2026 г., 19:14 UTC

Обсуждения рынка

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

13 апр. 2026 г., 18:59 UTC

Обсуждения рынка

Главные новостные события

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

13 апр. 2026 г., 18:59 UTC

Обсуждения рынка

Главные новостные события

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

13 апр. 2026 г., 18:43 UTC

Обсуждения рынка

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Сравнение c конкурентами

Изменение цены

Alnylam Pharmaceuticals Inc Прогноз

Целевая цена

By TipRanks

35.88% рост

Прогноз на 12 месяцев

Средняя 452.47 USD 35.88%

Максимум 549 USD

Минимум 330 USD

Основано на мнении 20 аналитиков Wall Street, спрогнозировавших целевые цены для Alnylam Pharmaceuticals Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

20 ratings

Покупка

Удержание

Продажа

Основано на мнении 20 аналитиков, присваивавших рейтинги акциям Alnylam Pharmaceuticals Inc – Данные за последние 3 месяца.

Техническая оценка

By Trading Central

256.565 / 269.81Поддержка и Сопротивление

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Настроения

By Acuity

154 / 348Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.